Cargando…

Clinical significance of dual-time-point 18F-FDG PET imaging in resectable non-small cell lung cancer

OBJECTIVE: The maximal standardized uptake value (SUVmax) of pulmonary lesions on dual-time-point (DTP) fluorodeoxyglucose positron emission tomography (FDG-PET) has been shown to be useful for differentiation between malignant and non-malignant pulmonary lesions, and also to be of value for intrath...

Descripción completa

Detalles Bibliográficos
Autores principales: Shimizu, Katsuhiko, Okita, Riki, Saisho, Shinsuke, Yukawa, Takuro, Maeda, Ai, Nojima, Yuji, Nakata, Masao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Japan 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4666280/
https://www.ncbi.nlm.nih.gov/pubmed/26254228
http://dx.doi.org/10.1007/s12149-015-1013-3
_version_ 1782403687526694912
author Shimizu, Katsuhiko
Okita, Riki
Saisho, Shinsuke
Yukawa, Takuro
Maeda, Ai
Nojima, Yuji
Nakata, Masao
author_facet Shimizu, Katsuhiko
Okita, Riki
Saisho, Shinsuke
Yukawa, Takuro
Maeda, Ai
Nojima, Yuji
Nakata, Masao
author_sort Shimizu, Katsuhiko
collection PubMed
description OBJECTIVE: The maximal standardized uptake value (SUVmax) of pulmonary lesions on dual-time-point (DTP) fluorodeoxyglucose positron emission tomography (FDG-PET) has been shown to be useful for differentiation between malignant and non-malignant pulmonary lesions, and also to be of value for intrathoracic nodal staging of non-small cell lung cancer (NSCLC). However, a few NSCLC lesions have been found to show decreased FDG uptake on delayed images, and the significance of this finding remains unknown. PATIENTS AND METHODS: We conducted a retrospective review of the data of 284 patients with NSCLC who underwent DTP FDG-PET before surgery. Cases of adenocarcinoma in situ and minimally invasive adenocarcinoma were excluded, because these lesions show little FDG uptake. Each patient was scanned at 60 min (early acquisition; SUV-E) and 115 min (delayed acquisition; SUV-D) after the radiopharmaceutical injection. The intratumoral retention index (RI) of 18F-FDG was measured for each examination by the DTP method. Recurrence-free survival (RFS) was determined by the Kaplan–Meier method and compared in relation to the SUV-E, SUV-D, and RI by univariate and multivariate analysis using models including the clinico-pathological prognostic factors. RESULTS: Of the 284 cases, the RI ≤ 0 was in 49 cases (17.3 %). This group of patients showed lower values of SUV-E and SUV-D, a smaller tumor size, and a lower rate of lymphatic invasion or vascular invasion. It was particularly noteworthy that lymph node metastasis was not histopathologically confirmed in any of these patients. Univariate analysis identified the RI, SUV-E and SUV-D, besides age, tumor size, lymph node metastasis, and tumor differentiation grade as predictors of the RFS. On the other hand, multivariate analysis identified the RI and lymph node metastasis, but not the SUV-E and SUV-D, as independent predictors of the RFS. CONCLUSIONS: This study demonstrated that DTP FDG-PET of the primary tumor in NSCLC can be useful to predict the RFS of the patients. In addition, this method may also be useful to predict the presence/absence of intrathoracic lymph node metastasis in these patients.
format Online
Article
Text
id pubmed-4666280
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Springer Japan
record_format MEDLINE/PubMed
spelling pubmed-46662802015-12-09 Clinical significance of dual-time-point 18F-FDG PET imaging in resectable non-small cell lung cancer Shimizu, Katsuhiko Okita, Riki Saisho, Shinsuke Yukawa, Takuro Maeda, Ai Nojima, Yuji Nakata, Masao Ann Nucl Med Original Article OBJECTIVE: The maximal standardized uptake value (SUVmax) of pulmonary lesions on dual-time-point (DTP) fluorodeoxyglucose positron emission tomography (FDG-PET) has been shown to be useful for differentiation between malignant and non-malignant pulmonary lesions, and also to be of value for intrathoracic nodal staging of non-small cell lung cancer (NSCLC). However, a few NSCLC lesions have been found to show decreased FDG uptake on delayed images, and the significance of this finding remains unknown. PATIENTS AND METHODS: We conducted a retrospective review of the data of 284 patients with NSCLC who underwent DTP FDG-PET before surgery. Cases of adenocarcinoma in situ and minimally invasive adenocarcinoma were excluded, because these lesions show little FDG uptake. Each patient was scanned at 60 min (early acquisition; SUV-E) and 115 min (delayed acquisition; SUV-D) after the radiopharmaceutical injection. The intratumoral retention index (RI) of 18F-FDG was measured for each examination by the DTP method. Recurrence-free survival (RFS) was determined by the Kaplan–Meier method and compared in relation to the SUV-E, SUV-D, and RI by univariate and multivariate analysis using models including the clinico-pathological prognostic factors. RESULTS: Of the 284 cases, the RI ≤ 0 was in 49 cases (17.3 %). This group of patients showed lower values of SUV-E and SUV-D, a smaller tumor size, and a lower rate of lymphatic invasion or vascular invasion. It was particularly noteworthy that lymph node metastasis was not histopathologically confirmed in any of these patients. Univariate analysis identified the RI, SUV-E and SUV-D, besides age, tumor size, lymph node metastasis, and tumor differentiation grade as predictors of the RFS. On the other hand, multivariate analysis identified the RI and lymph node metastasis, but not the SUV-E and SUV-D, as independent predictors of the RFS. CONCLUSIONS: This study demonstrated that DTP FDG-PET of the primary tumor in NSCLC can be useful to predict the RFS of the patients. In addition, this method may also be useful to predict the presence/absence of intrathoracic lymph node metastasis in these patients. Springer Japan 2015-08-08 2015 /pmc/articles/PMC4666280/ /pubmed/26254228 http://dx.doi.org/10.1007/s12149-015-1013-3 Text en © The Author(s) 2015 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
spellingShingle Original Article
Shimizu, Katsuhiko
Okita, Riki
Saisho, Shinsuke
Yukawa, Takuro
Maeda, Ai
Nojima, Yuji
Nakata, Masao
Clinical significance of dual-time-point 18F-FDG PET imaging in resectable non-small cell lung cancer
title Clinical significance of dual-time-point 18F-FDG PET imaging in resectable non-small cell lung cancer
title_full Clinical significance of dual-time-point 18F-FDG PET imaging in resectable non-small cell lung cancer
title_fullStr Clinical significance of dual-time-point 18F-FDG PET imaging in resectable non-small cell lung cancer
title_full_unstemmed Clinical significance of dual-time-point 18F-FDG PET imaging in resectable non-small cell lung cancer
title_short Clinical significance of dual-time-point 18F-FDG PET imaging in resectable non-small cell lung cancer
title_sort clinical significance of dual-time-point 18f-fdg pet imaging in resectable non-small cell lung cancer
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4666280/
https://www.ncbi.nlm.nih.gov/pubmed/26254228
http://dx.doi.org/10.1007/s12149-015-1013-3
work_keys_str_mv AT shimizukatsuhiko clinicalsignificanceofdualtimepoint18ffdgpetimaginginresectablenonsmallcelllungcancer
AT okitariki clinicalsignificanceofdualtimepoint18ffdgpetimaginginresectablenonsmallcelllungcancer
AT saishoshinsuke clinicalsignificanceofdualtimepoint18ffdgpetimaginginresectablenonsmallcelllungcancer
AT yukawatakuro clinicalsignificanceofdualtimepoint18ffdgpetimaginginresectablenonsmallcelllungcancer
AT maedaai clinicalsignificanceofdualtimepoint18ffdgpetimaginginresectablenonsmallcelllungcancer
AT nojimayuji clinicalsignificanceofdualtimepoint18ffdgpetimaginginresectablenonsmallcelllungcancer
AT nakatamasao clinicalsignificanceofdualtimepoint18ffdgpetimaginginresectablenonsmallcelllungcancer